Careers | Lonza

Careers

Join Lonza and discover career opportunities where your skills can make a meaningful difference by solving some of the most important challenges facing the healthcare industry today.

At Lonza, your next job is more than a career.

Embark on your career journey

Not ready to apply yet?

Join our Talent Community to stay connected and receive updates on the latest job opportunities.

Benefits

The flexible benefits we offer at Lonza reflect our commitment to our diverse community of world-class talent across our global network. We empower and support our employees in both their professional and personal endeavors. That’s why we are dedicated to providing a comprehensive range of benefits designed to support your health, well-being, and overall quality of life.

Learn more

Early Talent

At Lonza, medical advancements happen every day, driven by innovative minds like yours. Join us and be part of a team where your ideas make a meaningful difference.

Learn more

Hear from our people

Professional growth is fast at Lonza because we are fortunate to work on different types of drugs. This variety makes the work interesting and exciting as you never know what impact you will make.

Hailey
Analytical Chemist, Quality Control
Bend, Oregon

I recently led the time-sensitive development of a new chemical process for the production of a small-molecule COVID-19 drug substance, successfully scaling up from laboratory to large commercial scale manufacturing at rapid speed.

Alberto
Principal Scientist
Visp, Switzerland

Lonza has a reputation as a leading future-oriented company that genuinely strives for innovation. I have the opportunity here to learn about cutting-edge manufacturing technologies in pharma and develop myself professionally. Every contribution we make helps Lonza to bring therapies to life, and I appreciate being part of a community where people show respect and support for each other.

Dzmitry
Senior Quality Assurance Specialist, Growth Investments and Engineering (SGIE)
Visp, Switzerland

When I joined Lonza in 2019 as a Lead Engineer, I was excited by the idea of being part of the future of the pharmaceutical industry and having a role in shaping it. Knowing that I am having an impact helps to make each day rewarding. I know that I am part of changes that are making people’s lives better.

Eve
Engineer, Facilities Management
Singapore

Lonza

We have just signed a long-term commercial supply agreement for CASGEVY® with Vertex Pharmaceuticals.
We will manufacture CASGEVY® at our cGMP cell therapy manufacturing facilities in Geleen (NL), with plans to expand to our Portsmouth (US) facility.

t.co/JkREs9xzEa

Lonza

Today, we inaugurated our newest facility - the Innovaform Accelerator, to serve as a Center of Excellence for developing and innovating capsule-based manufacturing and delivery solutions for oral and pulmonary administration.

t.co/xIkqtkFhn3

Lonza

Highly potent active pharmaceutical ingredients, or HPAPIs, are a key capability for Lonza Small Molecules. They’re growing in importance in the pharmaceutical industry, with more than 1000 currently in development. But manufacturing them poses a range of technical and safety considerations.

Lonza Small Molecules senior director Charlie Johnson has just had an article published in Speciality Chemicals magazine that explains the challenges involved in making HPAPIs, and how CDMOs like Lonza can help. Making HPAPIs requires a significant investment in containment equipment, and expert operators to run them. This is something Lonza has put a substantial focus on in recent years, leaving us well placed to assist customers with their HPAPI projects.

If you’d like to know more about the challenges involved in making HPAPIs, you can read Charlie’s article in the magazine online. It’s on page 16. And do get in touch with us if you’d like to discover how Lonza Small Molecules can help make your HPAPI a reality.

In Focus - our July edition of the biologics newsletter from Lonza is ready for you to read.

Each month, we deliver deep analysis of industry trends, expert insights, and an overview of upcoming events - as well as the latest Lonza news and real-world customer stories.

This month's highlights include:
- News article: Patronus Progresses to Clinical Trials for Herpes Zoster Vaccine, Expressed Using Lonza’s CHOK1SV GS-KO® Cell Line and GS piggyBac® Technology
- Webinar: Advancing Early-Stage Bispecific Discovery Programs Towards Clinical Success
- An article: Considerations for Successful Tech Transfer of a Biologic Purification Process

Remember to subscribe to ensure you receive future editions of Biologics In Focus.

Today we reported solid financial results for the first half of 2024. With sales of CHF 3.1 billion for H1 2024, with our business performance well on track to deliver our Full-Year Outlook.

Business highlights in H1 included the signing of an agreement to acquire the Genentech large-scale mammalian facility in Vacaville (US) from Roche, which will double our global large-scale mammalian network and significantly increase our presence in the US. We welcomed Jean-Marc Huët as our new Chairman of the Board in May, and welcomed Wolfgang Wienand as our new CEO in July.

We also continued to make progress on our ESG commitments. Our emissions targets were validated by the Science Based Targets initiative (SBTi) in the First Half, and we signed a renewable energy certificate agreement that will enable our current facilities in the US to achieve 100% renewable electricity from 2026. As a result of our power agreements in Europe, the US and China, around 90% of our electricity will be renewable from 2026.

Read more about our progress in H1 2024 here:

Lonza is excited be at 2024's mRNA-Based Therapeutics Summit next week as a sponsor.

Visit us at booth and meet the team.

📅 July 30th - July 31st
📍 Booth

Join our colleague Dr Marcos Damasio on Tuesday July 30th for an insightful immunogenicity poster presentation on the risk assessment of mRNA therapeutics.

We are always looking for ways to make APIs more effectively, efficiently and safely. This is the focus of a new protocol developed by @Simon Wagschal and the Advanced Chemistry Technologies team in Visp, in collaboration with scientists at the in Austria.

Fluorine atoms are often found in API molecules because they are very useful features to introduce and modify biological activity. However, fluorinating agents are hazardous to use, and the more selective modern ones are expensive. Simon and team, which also included @Dominique M. Roberge and @Clara Bovino at Lonza Visp, found they could use the cheap reagent sulfur tetrafluoride, and by running the reactions in a continuous flow reactor, the whole process was made much less hazardous.

After this initial success, they have extended the methodology, and can now use it to make gem-difluoro compounds, where two fluorine atoms are attached to the same carbon atom. Numerous drugs contain gem-difluoro groups, but they are really challenging to make. But they managed to apply their fluorination methodology to the task, replacing the oxygen in a ketone with two fluorines.

If you would like to know more about these exciting developments, the original methodology was published in the journal Organic Process Research & Development last December, .

A paper describing the difluorination reaction has just been published by the same journal – and it’s been selected as editor’s choice.

If you’re interested in discovering more about how you can use this chemistry, get in touch with us to find out more.

Last week, we hosted an informal peer exchange with to discuss how companies are approaching the new ESG disclosure and due diligence obligations under the Swiss Code of Obligations.

@Andreas Bohrer, General Counsel and Company Secretary of Lonza, provided an insightful overview of the ESG aspects of the Swiss Code of Obligations, while our Global Sustainability and Responsible Sourcing team shared our approach to these new ESG requirements. The event was a valuable opportunity for peers to exchange ideas, network, and share best practices and challenges.

A big thank you to the UN Global Compact Network and all attendees for their active participation and contribution.

Our Latest Company News